The regulatory landscape governing CRISPR-based therapeutic development is evolving and uncertain. In this webinar, you will learn how Synthego's industry-leading Regulatory Affairs team leverages intelligence in the Cell & Gene therapy space to provide regulatory strategies that comply with FDA requirements and simplify the burden on therapeutic developers.

CRISPR cell and gene therapies are revolutionizing medicine, but transitioning from discovery to clinical trials is no straightforward task. The availability of high quality CRISPR reagents, coupled with the intricacies of uncertain regulatory frameworks and documentation processes, can cause significant delays during your progress to clinical success. Synthego has established itself as a leader in this area by expanding INDe and GMP manufacturing capabilities to stay ahead of the evolving regulatory guidelines, exemplified by numerous successfully supported IND submissions. Watch this webinar to learn how Synthego can support you in your CRISPR-based therapy development journey.

In this webinar hosted by CRISPR Medicine News you will learn:

  • The regulatory intelligence Synthego has gathered through our subject matter expertise and support of CRISPR-based cell & gene therapies
  • How Synthego has applied that intelligence to guide and support therapeutic developers during the IND submission process
  • How Synthego has used regulatory intelligence to optimize phase-specific products to enable greater clinical success in CRISPR-based therapeutic development

Watch on-demand now!